标题
Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
作者
关键词
-
出版物
Cancers
Volume 14, Issue 4, Pages 1026
出版商
MDPI AG
发表日期
2022-02-18
DOI
10.3390/cancers14041026
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma
- (2022) Isabella Lurje et al. Liver Cancer
- Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
- (2022) Felix Krenzien et al. Cancers
- Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
- (2021) Milind M. Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin
- (2021) Hyehyun Jeong et al. Cancers
- Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art
- (2021) Sven A. Lang et al. Expert Review of Gastroenterology & Hepatology
- Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study
- (2021) Ge Zhang et al. Frontiers in Oncology
- The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
- (2021) Dongxu Wang et al. Frontiers in Oncology
- Hypothermic Oxygenated Machine Perfusion (HOPE) Reduces Early Allograft Injury and Improves Post-Transplant Outcomes in Extended Criteria Donation (ECD) Liver Transplantation from Donation After Brain Death (DBD)
- (2021) Zoltan Czigany et al. ANNALS OF SURGERY
- A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer
- (2021) Jianming Xu et al. CANCER
- The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies
- (2021) Burcin Özdirik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
- (2021) Milind Javle et al. LANCET ONCOLOGY
- Merestinib monotherapy or in combination for japanese patients with advanced and/or metastatic cancer: A phase 1 study
- (2021) Toshihiko Doi et al. Cancer Medicine
- Current Surgical Management of Peri-Hilar and Intra-Hepatic Cholangiocarcinoma
- (2021) Andrea Lauterio et al. Cancers
- Hypothermic oxygenated machine perfusion for extended criteria donor allografts: Preliminary experience with extended organ preservation times in the setting of organ reallocation
- (2021) Sandra Pavicevic et al. ARTIFICIAL ORGANS
- ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study
- (2020) Jun Li et al. ANNALS OF SURGICAL ONCOLOGY
- First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study
- (2020) JOSEPH SGOUROS et al. ANTICANCER RESEARCH
- Biomarkers for hepatobiliary cancers
- (2020) Jean‐Charles Nault et al. HEPATOLOGY
- A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).
- (2020) Mitesh J. Borad et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial – REACHIN
- (2020) A. Demols et al. ANNALS OF ONCOLOGY
- The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma
- (2020) Amika Moro et al. ANNALS OF SURGICAL ONCOLOGY
- A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer
- (2020) Richard D. Kim et al. CANCER
- Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer
- (2020) Richard D. Kim et al. EUROPEAN JOURNAL OF CANCER
- Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Non-carriers
- (2020) Carolin V. Schneider et al. GASTROENTEROLOGY
- FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
- (2020) Lipika Goyal et al. JOURNAL OF CLINICAL ONCOLOGY
- Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
- (2020) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Ischemia-Reperfusion Injury in Marginal Liver Grafts and the Role of Hypothermic Machine Perfusion: Molecular Mechanisms and Clinical Implications
- (2020) Zoltan Czigany et al. Journal of Clinical Medicine
- FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
- (2020) Tanios S Bekaii-Saab et al. Future Oncology
- Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
- (2020) Shalini Makawita et al. Future Oncology
- Laparoscopic Liver Resection for Intrahepatic Cholangiocarcinoma: A Single-Center Experience
- (2020) Philipp Konstantin Haber et al. Journal of Laparoendoscopic & Advanced Surgical Techniques
- Cholangiocarcinoma 2020: the next horizon in mechanisms and management
- (2020) Jesus M. Banales et al. Nature Reviews Gastroenterology & Hepatology
- Insufficient future liver remnant and preoperative cholangitis predict perioperative outcome in perihilar cholangiocarcinoma
- (2020) Jan Bednarsch et al. HPB
- Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
- (2020) Yubin Hu et al. Cancer Management and Research
- Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study
- (2020) Zeyuan Qiang et al. Annals of Hepatology
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- (2020) Vivek Subbiah et al. LANCET ONCOLOGY
- Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results
- (2020) Makoto Ueno et al. BMC CANCER
- ARID1A alterations and their clinical significance in cholangiocarcinoma
- (2020) Achira Namjan et al. PeerJ
- Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program
- (2019) Markus Moehler et al. BMC CANCER
- Serum levels of miR-29, miR-122, miR-155 and miR-192 are elevated in patients with cholangiocarcinoma
- (2019) Sven H. Loosen et al. PLoS One
- Targeted Therapies in Cholangiocarcinoma: Emerging Evidence from Clinical Trials
- (2019) Maria Maddalena Simile et al. Medicina-Lithuania
- Cholangiocarcinoma: Epidemiology and risk factors
- (2019) Shahid A. Khan et al. LIVER INTERNATIONAL
- Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?
- (2019) Chiara Braconi et al. LIVER INTERNATIONAL
- Anatomical, histomorphological, and molecular classification of cholangiocarcinoma
- (2019) Timothy Kendall et al. LIVER INTERNATIONAL
- Diagnostic and prognostic biomarkers in cholangiocarcinoma
- (2019) Rocio I.R. Macias et al. LIVER INTERNATIONAL
- Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
- (2019) John N Primrose et al. LANCET ONCOLOGY
- Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
- (2019) Tianyi Fang et al. DISEASE MARKERS
- Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma
- (2019) Anwaar Saeed et al. Clinical Colorectal Cancer
- A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
- (2019) Martin H. Voss et al. CLINICAL CANCER RESEARCH
- High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study
- (2019) Chao Bi et al. BMC CANCER
- Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
- (2019) Rastilav Bahleda et al. CLINICAL CANCER RESEARCH
- The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma
- (2019) Georg Lurje et al. EJSO
- Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma
- (2019) Louisa Bolm et al. HPB
- Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
- (2019) Danielle Golub et al. Frontiers in Oncology
- The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
- (2019) Razelle Kurzrock et al. CLINICAL CANCER RESEARCH
- Reply to: Does lymphovascular invasion really associate with decreased overall survival for patients with resected cholangiocarcinoma?
- (2019) Jan Bednarsch et al. EJSO
- Left- versus right-sided hepatectomy with hilar en-bloc resection in perihilar cholangiocarcinoma
- (2019) Jan Bednarsch et al. HPB
- Chirurgische Therapie maligner Gallengangserkrankungen
- (2019) M. Schmelzle et al. CHIRURG
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of ALPPS in intrahepatic cholangiocarcinoma
- (2019) Jan Bednarsch et al. LANGENBECKS ARCHIVES OF SURGERY
- Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma
- (2019) Kai-Qian Zhou et al. Hepatobiliary Surgery and Nutrition
- A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer
- (2018) Renuka V. Iyer et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Transplantation Versus Resection for Hilar Cholangiocarcinoma
- (2018) Eric Vibert et al. ANNALS OF SURGERY
- Targeting cholangiocarcinoma
- (2018) Joachim C. Mertens et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- The diagnostic value of five serum tumor markers for patients with cholangiocarcinoma
- (2018) Yuanfu Qiu et al. CLINICA CHIMICA ACTA
- Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention
- (2018) Maeve A Lowery et al. CLINICAL CANCER RESEARCH
- Hilar en bloc resection for hilar cholangiocarcinoma in patients with limited liver capacities—preserving parts of liver segment 4
- (2018) Sven Jonas et al. European Surgery-Acta Chirurgica Austriaca
- Prognostic biomarkers for cholangiocarcinoma and their clinical implications
- (2018) Charupong Saengboonmee et al. Expert Review of Anticancer Therapy
- Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma
- (2018) Chirag Nepal et al. HEPATOLOGY
- Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma
- (2018) Qiang Huang et al. Journal of Cancer Research and Therapeutics
- Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
- (2018) Milind Javle et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis
- (2018) Yoshinobu Ikeno et al. Journal of Translational Medicine
- Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
- (2018) Hendrik‐Tobias Arkenau et al. ONCOLOGIST
- Diagnostic and prognostic value of microRNAs in cholangiocarcinoma: a systematic review and meta-analysis
- (2018) Chao Sun et al. Cancer Management and Research
- Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms
- (2018) G. Lurje et al. CHIRURG
- Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma
- (2018) Chaobin He et al. Journal of Cancer
- LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
- (2018) M Javle et al. ANNALS OF ONCOLOGY
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
- (2018) Vincenzo Mazzaferro et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Serum Nardilysin, a Surrogate Marker for Epithelial–Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection
- (2018) Tomoaki Yoh et al. CLINICAL CANCER RESEARCH
- Prognostic role of BAP-1 and PBRM-1 expression in intrahepatic cholangiocarcinoma
- (2018) Samantha Sarcognato et al. VIRCHOWS ARCHIV
- Characterisation of the immune-related transcriptome in resected biliary tract cancers
- (2017) Michele Ghidini et al. EUROPEAN JOURNAL OF CANCER
- MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma
- (2017) Hao Li et al. HEPATOLOGY
- Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study
- (2017) Hideo Saka et al. INVESTIGATIONAL NEW DRUGS
- Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma
- (2017) Sven H. Loosen et al. JOURNAL OF HEPATOLOGY
- Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study
- (2017) Finn Ole Larsen et al. ONCOLOGY
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma
- (2017) Ze-Wu Meng et al. TUMOR BIOLOGY
- CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma
- (2017) Da-Wei Huang et al. OncoTargets and Therapy
- Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma
- (2017) Yi Xu et al. OncoTargets and Therapy
- Identification of microRNAs as biomarkers for cholangiocarcinoma detection: A diagnostic meta-analysis
- (2017) J. Zhou et al. Clinics and Research in Hepatology and Gastroenterology
- Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection
- (2017) Chu-Yu Jing et al. Oncotarget
- Increased Expression of miR-29a and Its Prognostic Significance in Patients with Cholangiocarcinoma
- (2017) Yingbin Deng et al. Oncology Research and Treatment
- Expression of Ki-67, Bax and p73 in patients with hilar cholangiocarcinoma
- (2017) Wei Zhao et al. Cancer Biomarkers
- CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma
- (2017) Sven H. Loosen et al. Scientific Reports
- Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas
- (2016) Motoko Sasaki et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
- (2016) John Bridgewater et al. BMC CANCER
- Biliary cancer: Utility of next-generation sequencing for clinical management
- (2016) Milind Javle et al. CANCER
- HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
- (2016) Salvatore Galdy et al. CANCER AND METASTASIS REVIEWS
- CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment
- (2016) Malinee Thanee et al. CANCER SCIENCE
- Screening for circulating RAS/RAF mutations by multiplex digital PCR
- (2016) Rikke Fredslund Andersen et al. CLINICA CHIMICA ACTA
- Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma
- (2016) Zhenzhen Liang et al. DIGESTIVE AND LIVER DISEASE
- N-myc downstream-regulated gene 2 inhibits human cholangiocarcinoma progression and is regulated by leukemia inhibitory factor/MicroRNA-181c negative feedback pathway
- (2016) Jiabei Wang et al. HEPATOLOGY
- Ring finger protein 43 expression is associated with genetic alteration status and poor prognosis among patients with intrahepatic cholangiocarcinoma
- (2016) Chutima Talabnin et al. HUMAN PATHOLOGY
- A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers
- (2016) Laura W. Goff et al. INVESTIGATIONAL NEW DRUGS
- Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma
- (2016) Ban Seok Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Impact of stroma LOXL2 overexpression on the prognosis of intrahepatic cholangiocarcinoma
- (2016) Damien Bergeat et al. JOURNAL OF SURGICAL RESEARCH
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Aberrant expression of B7-H4 correlates with poor prognosis and suppresses tumor-infiltration of CD8+ T lymphocytes in human cholangiocarcinoma
- (2016) XIN ZHAO et al. ONCOLOGY REPORTS
- Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma
- (2016) Hongchen Zhang et al. TUMOR BIOLOGY
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Dickkopf-1 expression is associated with tumorigenity and lymphatic metastasis in human hilar cholangiocarcinoma
- (2016) Xiang-de Shi et al. Oncotarget
- Prognostic Role of Mucin Antigen MUC4 for Cholangiocarcinoma: A Meta-Analysis
- (2016) Bingmin Li et al. PLoS One
- Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma
- (2015) Finn Ole Larsen et al. ACTA ONCOLOGICA
- Prognostic Impact of Peritumoral IL-17-Positive Cells and IL-17 Axis in Patients with Intrahepatic Cholangiocarcinoma
- (2015) Kei Asukai et al. ANNALS OF SURGICAL ONCOLOGY
- Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma
- (2015) Yong Li et al. Asian Pacific Journal of Cancer Prevention
- High Expression of Matrix Metalloproteinase-11 indicates Poor Prognosis in Human Cholangiocarcinoma
- (2015) Taweesak Tongtawee et al. Asian Pacific Journal of Cancer Prevention
- Prognostic molecular markers in resected extrahepatic biliary tract cancers; a systematic review and meta-analysis of immunohistochemically detected biomarkers
- (2015) Robert P Jones et al. Biomarkers in Medicine
- Identification of a novel microRNA signature associated with intrahepatic cholangiocarcinoma (ICC) patient prognosis
- (2015) Mei-Yin Zhang et al. BMC CANCER
- Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
- (2015) Seung Tae Kim et al. BMC CANCER
- microRNA-34a inhibits epithelial mesenchymal transition in human cholangiocarcinoma by targeting Smad4 through transforming growth factor-beta/Smad pathway
- (2015) Pengfei Qiao et al. BMC CANCER
- Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
- (2015) Alexander Stein et al. BMC CANCER
- Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-typeKRASadvanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
- (2015) Francesco Leone et al. CANCER
- Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma
- (2015) Mitesh J. Borad et al. CURRENT OPINION IN GASTROENTEROLOGY
- Prognostic evaluation of mucin-5AC expression in intrahepatic cholangiocarcinoma, mass-forming type, following hepatectomy
- (2015) T. Abe et al. EJSO
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- HER2/neu-directed therapy for biliary tract cancer
- (2015) Milind Javle et al. Journal of Hematology & Oncology
- Genomic spectra of biliary tract cancer
- (2015) Hiromi Nakamura et al. NATURE GENETICS
- The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma
- (2015) Yimin Wang et al. PLoS One
- Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma
- (2015) Li-Juan Wang et al. Oncotarget
- Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma
- (2015) Qingbao Cheng et al. Scientific Reports
- Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis
- (2015) Bin Liang et al. MEDICAL SCIENCE MONITOR
- miR-221 Promotes Epithelial-Mesenchymal Transition through Targeting PTEN and Forms a Positive Feedback Loop with β-catenin/c-Jun Signaling Pathway in Extra-Hepatic Cholangiocarcinoma
- (2015) Jianguo Li et al. PLoS One
- A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
- (2014) S. Pant et al. ANNALS OF ONCOLOGY
- A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
- (2014) A. Santoro et al. ANNALS OF ONCOLOGY
- Association of NRF2 Polymorphism with Cholangiocarcinoma Prognosis in Thai Patients
- (2014) Tueanjai Khunluck et al. Asian Pacific Journal of Cancer Prevention
- SOX4 is associated with poor prognosis in cholangiocarcinoma
- (2014) Weishan Wang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Prognostic significance of circulating intact and cleaved forms of urokinase plasminogen activator receptor in inoperable chemotherapy treated cholangiocarcinoma patients
- (2014) M. Grunnet et al. CLINICAL BIOCHEMISTRY
- Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
- (2014) D. R. Borger et al. CLINICAL CANCER RESEARCH
- Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma
- (2014) Li Huang et al. DIGESTIVE DISEASES AND SCIENCES
- Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
- (2014) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- CD98 is a promising prognostic biomarker in biliary tract cancer
- (2014) Kyoichi Kaira et al. Hepatobiliary & Pancreatic Diseases International
- Survival Outcomes and Prognostic Factors of Surgical Therapy for All Potentially Resectable Intrahepatic Cholangiocarcinoma: a Large Single-Center Cohort Study
- (2014) Xianwu Luo et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator
- (2014) Runglawan Silakit et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma
- (2014) Laurent Sulpice et al. JOURNAL OF SURGICAL RESEARCH
- Cholangiocarcinoma
- (2014) Nataliya Razumilava et al. LANCET
- Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
- (2014) Chaitanya R. Churi et al. PLoS One
- Hepatoma-derived growth factor: a novel prognostic biomarker in intrahepatic cholangiocarcinoma
- (2014) Sen Guo et al. TUMOR BIOLOGY
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
- (2013) J. W. Valle et al. ANNALS OF ONCOLOGY
- Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis
- (2013) Anthony T. Ruys et al. ANNALS OF SURGICAL ONCOLOGY
- A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
- (2013) J K Lee et al. BRITISH JOURNAL OF CANCER
- Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis
- (2013) P. Chusorn et al. TUMOR BIOLOGY
- A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma
- (2013) ELISA PAOLICCHI et al. Oncology Letters
- Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer
- (2012) L. H. Jensen et al. ANNALS OF ONCOLOGY
- High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery
- (2012) Ruo-Yu Shi et al. CANCER
- HER2/neu May Not Be an Interesting Target in Biliary Cancers: Results of an Early Phase II Study with Lapatinib
- (2012) Joshua Peck et al. ONCOLOGY
- Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type
- (2012) Michiyo Higashi et al. PATHOBIOLOGY
- High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis
- (2012) Parichut Thummarati WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors
- (2011) Jesper B. Andersen et al. GASTROENTEROLOGY
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
- (2011) Anthony B. El-Khoueiry et al. INVESTIGATIONAL NEW DRUGS
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
- (2011) Jeeyun Lee et al. LANCET ONCOLOGY
- Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group GI06-101
- (2011) E. G. Chiorean et al. ONCOLOGIST
- Genetic Variations in Angiogenesis Pathway Genes Predict Tumor Recurrence in Localized Adenocarcinoma of the Esophagus
- (2010) Georg Lurje et al. ANNALS OF SURGERY
- miR-373 Negatively Regulates Methyl-CpG-Binding Domain Protein 2 (MBD2) in Hilar Cholangiocarcinoma
- (2010) Yongjun Chen et al. DIGESTIVE DISEASES AND SCIENCES
- Report of a Multicenter Phase II Trial Testing a Combination of Biweekly Bevacizumab and Daily Erlotinib in Patients With Unresectable Biliary Cancer: A Phase II Consortium Study
- (2010) Sam J. Lubner et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
- (2010) Birgit Gruenberger et al. LANCET ONCOLOGY
- EGFR Signaling and Drug Discovery
- (2010) Georg Lurje et al. ONCOLOGY
- Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma
- (2009) G. Lurje et al. ANNALS OF ONCOLOGY
- Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
- (2009) C Bengala et al. BRITISH JOURNAL OF CANCER
- A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
- (2009) Ramesh K. Ramanathan et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Prognostic Assessment of Three Single-Nucleotide Polymorphisms (GNB3825C>T,BCL2-938C>A,MCL1-386C>G) in Extrahepatic Cholangiocarcinoma
- (2009) Christian Dominik Fingas et al. CANCER INVESTIGATION
- Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study
- (2009) Andrew X Zhu et al. LANCET ONCOLOGY
- Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications
- (2009) Georg Lurje et al. Journal of Oncology
- Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer
- (2008) G. Lurje et al. ANNALS OF ONCOLOGY
- Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab
- (2008) G. Lurje et al. CLINICAL CANCER RESEARCH
- Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma
- (2008) Alphonse E Sirica WORLD JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started